Neuromyelitis Optica Spectrum Disorder Clinical Trials in Washington D.C., District of Columbia
2 recruitingWashington D.C., District of Columbia
Showing 1–2 of 2 trials
Recruiting
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
Neuromyelitis Optica Spectrum DisorderNMOSDAQP4+ NMOSD
Alexion Pharmaceuticals, Inc.122 enrolled33 locationsNCT05966467
Recruiting
Phase 2Phase 3
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
Neuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc.12 enrolled21 locationsNCT05346354